載入...
Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry
The authors sought to retrospectively analyze the real‐world evidence on aliskiren in diabetic patients with or without concomitant renin‐angiotensin system (RAS) blocker use based on the Registry for Ambulant Therapy With RAS Inhibitors in Hypertension Patients in Germany (3A). Of 14,986 patients i...
Na minha lista:
| 發表在: | J Clin Hypertens (Greenwich) |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8031948/ https://ncbi.nlm.nih.gov/pubmed/27094460 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jch.12828 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|